Sensitizing substances including isobornyl acrylate ( IBOA ) in diabetes devices are predicted as skin sensitizers by the non‐animal assay KeratinoSens™ —Are better preventive approaches possible?
Contact Dermatitis · 2024
DOI: 10.1111/cod.14581 ↗At a glance
Fallbericht in Contact Dermatitis, 2024. Written by Madeleine Sjöberg and 4 co-authors. Institution: Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Major MEDLINE topics: Acrylates, Dermatitis, Allergic Contact, Camphanes. 10 references. The full text is freely available (open access, CC BY 4.0). Funded by: Karolinska Institutet.
Topics: Diabetes mellitus
Abstract (original language)
Ebda abstract disponibbli.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
ORCID profiles: Andrea Montano Montes, Carola Lidén, Hanna L Karlsson
Funding
- Karolinska Institutet
Cite
APA
Sjöberg, M., Carlander, U., Montes, A. M., Lidén, C., & Karlsson, H. L. (2024). Sensitizing substances including isobornyl acrylate ( IBOA ) in diabetes devices are predicted as skin sensitizers by the non‐animal assay KeratinoSens™ —Are better preventive approaches possible?. Contact Dermatitis. https://doi.org/10.1111/cod.14581
Vancouver
Sjöberg M, Carlander U, Montes AM, Lidén C, Karlsson HL. Sensitizing substances including isobornyl acrylate ( IBOA ) in diabetes devices are predicted as skin sensitizers by the non‐animal assay KeratinoSens™ —Are better preventive approaches possible?. Contact Dermatitis. 2024. doi:10.1111/cod.14581
BibTeX
@article{Sjberg2024,
author = {Sjöberg, Madeleine and Carlander, Ulrika and Montes, Andrea Montano and Lidén, Carola and Karlsson, Hanna L},
title = {Sensitizing substances including isobornyl acrylate ( IBOA ) in diabetes devices are predicted as skin sensitizers by the non‐animal assay KeratinoSens™ —Are better preventive approaches possible?},
journal = {Contact Dermatitis},
year = {2024},
doi = {10.1111/cod.14581}
}
EUVIMED